{"id":389792,"date":"2022-08-12T00:00:00","date_gmt":"2022-08-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0002-2022-biopharma-alzheimers-disease-access-reimbursement-us-2022\/"},"modified":"2026-04-24T05:20:06","modified_gmt":"2026-04-24T05:20:06","slug":"acrecg0002-2022-biopharma-alzheimers-disease-access-reimbursement-us-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0002-2022-biopharma-alzheimers-disease-access-reimbursement-us-2022\/","title":{"rendered":"Alzheimer&#8217;s Disease | Access &#038; Reimbursement | US | 2022"},"content":{"rendered":"<p>Until recently, FDA-approved treatments for Alzheimer\u2019s disease (AD) were limited to modestly effective symptomatic agents (e.g., donepezil, memantine), but in 2021, Biogen \/ Eisai\u2019s Aduhelm (aducanumab) became the first potential disease-modifying therapy (DMT) approved for AD\u2014an event marked by considerable controversy. Other DMTs (e.g., from Eisai \/ Biogen, Eli Lilly, Roche, Novo Nordisk) and symptomatic agents for treating AD-associated psychosis (Acadia\u2019s Nuplazid) and agitation (Lundbeck \/ Otsuka\u2019s Rexulti, Avanir \/ Otsuka\u2019s AVP-786, Axsome\u2019s AXS-05) are advancing through late-phase development with near-term launch potential; their approval could meaningfully alter the dynamics of this market, driven by clear need, strong market demand, and premium pricing\u2014but only if these treatments are accessible. As the AD therapy market enters a new era, understanding neurologists\u2019 preferences for and expectations from new therapeutics, counterpoised by payers\u2019 receptivity to high-priced brands entering a highly underserved but heavily generic market, will be key for pharmaceutical companies developing new drugs or considering entering this wide-open arena.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What impact does the cost of AD treatment have on prescribers and payers today? How will cost drive treatment choices in the future?<\/li>\n<li>What is the current state of coverage of key therapies used or approved for AD in the United States? What restrictions do payers impose, and how do market access dynamics influence surveyed neurologists\u2019 prescribing?<\/li>\n<li>What coverage and uptake would be expected for future anti-A\u03b2 monoclonal antibodies if their efficacy is confirmed in Phase III clinical trials? What clinical and nonclinical differentiators would drive preferential use and coverage terms?<\/li>\n<li>How receptive are payers to drugs in late-phase development for key neuropsychiatric symptoms? What coverage decisions do they anticipate? How do neurologists expect to prescribe the agents?<\/li>\n<li>What actions can developers take to optimize market access?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>U.S. Access &#038; Reimbursement<\/em> provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.<\/p>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key drugs: <\/strong>AChEIs, memantine, Adlarity, Namzaric, Nuplazid, Rexulti, Aduhelm, lecanemab, donanemab, gantenerumab, semaglutide, AVP-786, AXS-05.<\/p>\n<p><strong>Key companies: <\/strong>Biogen,<strong>\u00a0<\/strong>Eisai, Novartis, Novo Nordisk, AbbVie, Corium, Eli Lilly, Roche, Johnson &#038; Johnson, Lundbeck \/ Otsuka, Acadia Pharmaceuticals.<\/p>\n","protected":false},"template":"","class_list":["post-389792","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389792\/revisions"}],"predecessor-version":[{"id":576221,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389792\/revisions\/576221"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}